Clinical Trial

Experimental Treatment for High-Risk Pulmonary Nodules

Study Description

Pembrolizumab in Treating Patients With High-Risk Pulmonary Nodules

This phase II trial studies how well pembrolizumab works in treating patients with high-risk pulmonary nodules. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the pre-malignant cells, and may inhibit the progression of pre-malignant cells into invasive cancer cells.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Best Practice

Receive standard of care

Biological - Pembrolizumab

Given IV

Quality-of-Life Assessment

Ancillary studies

Additional Information

Official Study Title

Randomized Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)

Clinical Trial ID

NCT03634241

ParticipAid ID

b826ge